Pharmaceutical industry – Page 25
-
BusinessTeva to cut 14,000 jobs
Saddled with debt in an increasingly competitive generic drug industry, the Israel-headquartered giant begins a difficult transformation
-
OpinionFor the sake of argument
It’s important to recognise which disputes can actually be resolved by science
-
ResearchSuzuki–Miyaura–hydrogenation targets 3D drugs
Researchers design a new pathway to make sp3 enriched drug molecules
-
BusinessPharmaceuticals roundup 2017
Political influence has strongly shaped industry activity in the past year
-
BusinessBayer and J&J lose first blood thinner lawsuit
US jury fines Xarelto makers $27.8 million for downplaying drug risks
-
BusinessMerck & Co and Qiagen to build UK research hubs
Almost 2000 jobs to be created at research centres in Manchester and London
-
BusinessEuropean drug regulator heads to Amsterdam
Brexit drives EMA to relocate, taking hundreds of jobs and significant expertise away from UK
-
OpinionBeyond buckets and batches
Embracing flow chemistry means leaving behind some faithful friends
-
BusinessTargeting rare diseases
Is working on genetic mutations that affect only a few in every thousand people risky?
-
BusinessBayer forms cancer-drug partnership with Loxo
Alliance could see Loxo net up to $1.55bn in upfront and milestone payments
-
FeatureStaying one step ahead of the game
Clare Sansom examines the need for agile drug development when tackling emerging viral disease outbreaks
-
BusinessChina clamps down on polluting factories
Thousands of factories face closure or sanctions as authorities exercise new powers to curb air and water pollution
-
BusinessChuck Norris versus gadolinium
US action star is suing 11 drug firms for $10m, claiming his wife was poisoned by gadolinium from her MRIs
-
BusinessValeant relinquishes female libido drug
Struggling firm is returning Sprout Pharmaceuticals subsidiary to original shareholders to resolve dispute over marketing
-
BusinessGenerics firms Amneal and Impax to merge
Deal continues consolidation trend, based on portfolio expansion and simplifying supply chains
-
BusinessNovartis to buy AAA for radioligand cancer drugs
$3.9bn deal follows European approval of Advanced Accelerator Applications’ first-in-class radionuclide drug Lutathera
-
BusinessLilly and CureVac to collaborate on mRNA cancer vaccines
Deal could see CureVac net up to $1.8 billion in upfront and milestone payments
-
BusinessGSK’s shingles vaccine gets thumbs up in North America
Inoculation slated to be a blockbuster
-
BusinessJudges overturn J&J talc cancer claims
Two new rulings follow trend of reversing large jury-awarded damages as firm works through thousands of cases
-
OpinionRise of the biologics
Antibodies, RNA and gene therapy don’t necessarily compete with small molecule drugs – and they all rely on chemistry